Boston Scientific (BSX) Total Current Liabilities (2009 - 2026)

Boston Scientific has disclosed Total Current Liabilities across 18 years of filings, most recently posting $6.4 billion for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 23.85% year-over-year to $6.4 billion; the TTM figure through Jun 2026 stood at $6.4 billion (up 23.85% YoY), while the FY2025 annual figure was $5.4 billion, down 15.0% from the prior year.
• Total Current Liabilities came in at $6.4 billion for Q2 2026 at Boston Scientific, up from $4.6 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $6.4 billion in Q2 2026 to a low of $3.5 billion in Q3 2022.
• Average Total Current Liabilities over 5 years is $4.9 billion, with a median of $4.9 billion recorded in 2023.
• Year-over-year, Total Current Liabilities rose 29.72% in 2024 and dropped 15.0% in 2025.
• Over 5 years, Total Current Liabilities stood at $3.8 billion in 2022, then grew by 29.71% to $4.9 billion in 2023, then rose by 29.72% to $6.4 billion in 2024, then decreased by 15.0% to $5.4 billion in 2025, then gained by 18.18% to $6.4 billion in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $6.4 billion in Q2 2026, $4.6 billion in Q1 2026, and $5.4 billion in Q4 2025.